Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor | Zendy

Gregory Y.H. Lip | Zendy; Flemming Skjøth | Zendy; Peter Brønnum Nielsen | Zendy; Jette Nordstrøm Kjældgaard | Zendy; Torben Bjerregaard Larsen | Zendy

Open Access

Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor

Author(s) -

Gregory Y.H. Lip,

Flemming Skjøth,

Peter Brønnum Nielsen,

Jette Nordstrøm Kjældgaard,

Torben Bjerregaard Larsen

Publication year - 2017

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2017.1883

Subject(s) - rivaroxaban , medicine , apixaban , dabigatran , atrial fibrillation , warfarin , stroke (engine) , risk factor , embolism , cardiology , mechanical engineering , engineering

The randomized clinical trials comparing nonvitamin K antagonist oral anticoagulants (NOACs) vs warfarin largely focused on recruiting high-risk patients with atrial fibrillation with more than 2 stroke risk factors, with only the trials testing dabigatran or apixaban including few patients with 1 stroke risk factor. Despite this, regulatory approvals of all NOACs have been based on stroke prevention for patients with atrial fibrillation with 1 or more stroke risk factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research